Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Positioning, Utilization and Effectiveness of Osimertinib in First Line in Real-life Therapeutic Strategy in France Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations

NCT05103605 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT05103605
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05103605 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Positioning, Utilization and Effectiveness of Osimertinib in First Line in Real-life Therapeutic Strategy in France Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients With Activating EGFR Mutations
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Active, not recruiting
Start date
May 12, 2021
Completion date
January 15, 2026
Enrollment
274 (actual)
Sites
46

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung cancer